ClinicalTrials.gg

Central Nervous System Neoplasms clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 699 studies for Central Nervous System Neoplasms across more than 10 countries. 66 are recruiting or about to start. 461 of them are mainly about Central Nervous System Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its 14 narrower conditions too, such as Brain Neoplasms: 3,573 studies, 820 open.

ClinicalTrials.gov finds 4,642 studies for Central Nervous System Neoplasms. How that becomes 699 here

This page counts the studies the registry files under Central Nervous System Neoplasms, and those it files under no condition that list Central Nervous System Neoplasmsthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 4,642Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −2,724Filed under a narrower condition, counted on its own pageBrain Neoplasms 2,077 · Pituitary Neoplasms 168 · Meningioma 131 · Meningeal Carcinomatosis 102 · Diffuse Intrinsic Pontine Glioma 82 · Spinal Cord Neoplasms 70 · 8 more
  3. −4List Central Nervous System Neoplasms as a condition, but the registry did not file them under itMost often written as “Recurrent Primary Malignant Central Nervous System Neoplasm” (1), “Refractory Primary Malignant Central Nervous System Neoplasm” (1), and “Locally Advanced Primary Malignant Central Nervous System Neoplasm” (1). The registry filed them under other conditions only, most often Medulloblastoma (2) and Rhabdoid Tumor (2).
  4. −1,215Match it another way11 name it in the title, 1 in a keyword, and 1,203 by a synonym or other text the search reads.
  5. 699The count on this page3 of them list Central Nervous System Neoplasms in their own words; the registry filed them under no condition.

Status

Completed
441
Terminated
71
Recruiting
57
Status unknown
53
Withdrawn
35
Active, not recruiting
32

Phase

Phase 2
299
Phase 1
289
Phase 3
40
Early Phase 1
7
Phase 4
1

Where

United States
547
Canada
90
United Kingdom
52
Australia
46
France
45
Switzerland
41

Who develops what

Add Central Nervous System Neoplasms to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 6 programs from 5 companies, 0 with this as their studies’ main aim; 1 with a live phase 3 study; 1 primary completion in the next 12 months.

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
PaclitaxelRecent, limited
Evidence
  • NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Paclitaxel” · registered Aug 2023
Hoffmann-La Roche12% of its industry studiesUS: off-patent, 10 generics marketed11 study
CarboplatinRecent, limitedPhase 4 trial recorded
Evidence
  • NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Carboplatin” · registered Aug 2023
Eli Lilly and Company16% of its industry studies11 study
abemaciclibRecent, limited
Evidence
  • NCT05386108 · Menarini Group · Phase 2 · live · background · “Abemaciclib” · registered May 2022
Eli Lilly and Company98% of its industry studiesUS: Eli Lilly and Company (FDA 2017)EU: Eli Lilly and Company (EMA 2018)11 study

6 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 6 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 31 Jul 2027 est.Rhenium Re 186 Obisbemeda · Cerenome · Phase 2 registry mapping onlyNCT07098806 Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases — primary endpoint: Maximum Tolerated Dose · 24 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Central Nervous System Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Alkylating agents 2 open · Tyrosine kinase inhibitors (TKIs) 2 open · Immune checkpoint inhibitors 2 open · Antimitotic agents 44 · Antimetabolites 26

Coming up

28studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 57 Central Nervous System Neoplasms studies recruiting now, 35 (61%) set no upper age limit and 19 (33%) stop at 75 or younger. 35 (61%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 6 (11%) take healthy volunteers.

Recruiting studies that take each age, of 57
AgeWomenMen
1033 (58%)33 (58%)
1855 (96%)55 (96%)
3039 (68%)39 (68%)
4038 (67%)38 (67%)
5038 (67%)38 (67%)
6538 (67%)38 (67%)
7538 (67%)38 (67%)
8538 (67%)38 (67%)

Across all 699 studies, recruiting or not: 40% stop at 75 or younger and 36% at 65; 46% take children; <1% are for women only and 1% for men only; 2% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Central Nervous System Neoplasms studies take

Of 54 phase 2 interventional studies under Central Nervous System Neoplasms, half reached primary completion within 58 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 146 mo37–73 · 52 studies—47 mo37–73 · 43 studies
Phase 1/258 mo48–85 · 35 studies——
Phase 258 mo44–77 · 54 studies—56 mo44–77 · 50 studies
Interventional, no phase127 mo43–175 · 18 studies——
Observational92 mo41–… · 39 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 699. Browse all 699 → or search them.